Program
Cabergoline
Also written as “Cabergoline tablets test formulation”, “Cabergoline tablets reference formulation” and “Cabergoline tablets”.
Its studies are mostly in Hyperprolactinemia · Restless Legs Syndrome · Adrenocortical Hyperfunction · Acromegaly · Fasting, led by 4 companies.
Drug pageCabergoline: every studyAll 52 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 22 open or running | phase 3since Aug 3, 2025 | May 29, 2025 | Nov 21, 2026phase 3 · NCT07124221 |
| Novartisits history only | 20 open or running | phase 4since Sep 13, 2006 | Sep 13, 2006 | none ahead |
| Par Healthits history only | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Pfizerits history only | 20 open or running | phase 3since Feb 19, 2008 | Feb 19, 2008 | none ahead |
Also a collaborator on its studies: Anapharm.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2025First study: phase 1 study in HyperprolactinemiaFirst studyNCT07008417 · 72 enrolled · China
- Aug 3, 2025Phase 3 study in HyperprolactinemiaNCT07124221 · 382 planned · China
Ahead
- Nov 21, 2026Primary completion: phase 3 study in HyperprolactinemiaNCT07124221
TargetBeta
“Dopamine D2 receptor agonist”ChEMBL 37, by rule
Other programs on DRD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| rotigotinerule | UCB | phase 4 | 64 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 15 |
| cariprazinerule | AbbVie | phase 3 | 41 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
| pridopidinerule | prilenia | phase 3 | 10 |
Studies
All 2 Changchun GeneScience Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07124221Hyperprolactinemia · China | 3 | Recruiting | Nov 21, 2026 | 382 |
| NCT07008417Hyperprolactinemia · China | 1 | Active, not recruiting | Feb 3, 2026 | 72 |
How it is read
Names in the registry
- “Cabergoline”, 3 entries
- “Cabergoline tablets test formulation”, 1 entry
- “Cabergoline tablets reference formulation”, 1 entry
- “Cabergoline tablets”, 1 entry
- “Pasireotide with or without cabergoline”, 1 entry
Conditions, from the studies’ own filings
- Hyperprolactinemia, 2 studies
- Restless Legs Syndrome, 2 studies
- Adrenocortical Hyperfunction, 1 study
- Acromegaly, 1 study
- Fasting, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.